Atnaujinkite slapukų nuostatas

El. knyga: Flow Cytometry in Hematopathology: A Visual Approach to Data Analysis and Interpretation

4.00/5 (6 ratings by Goodreads)
, ,
  • Formatas: PDF+DRM
  • Išleidimo metai: 04-Mar-2008
  • Leidėjas: Humana Press Inc.
  • Kalba: eng
  • ISBN-13: 9781597451628
Kitos knygos pagal šią temą:
Flow Cytometry in Hematopathology: A Visual Approach to Data Analysis and InterpretationDidesnis paveikslėlis
  • Formatas: PDF+DRM
  • Išleidimo metai: 04-Mar-2008
  • Leidėjas: Humana Press Inc.
  • Kalba: eng
  • ISBN-13: 9781597451628
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

With step-by-step instructions for flow cytometry (FCM) immunophenotyping of hematopoietic malignancies along with a comprehensive set of images and examples and completely updated materials on certain T-cell disorders and DNA dyes, this edition covers both simple and complex specimens focusing on visual pattern analysis. It gives a framework to use in approaching analysis of FCM, including pitfalls, general aspects of analysis and interpretation and an overview of immunologic markers currently in use in the FCM lab, practical aspects that can affect analysis and interpretation ranging from sample staining to fluorochrome conjugation and approach to DNA data, FCM analysis on early homogeneous samples (such as the influence of fluorescence dynamic range and aberrant beta-cell profiles) and on heterogeneous samples (such as abnormal plasma cells, increased cosinophils and coexisting malignancies), and FCM interpretation and reporting, covering a full range of findings. The accompanying CD-ROM includes 100 case studies. Annotation ©2008 Book News, Inc., Portland, OR (booknews.com)

The second edition of this volume reflects the recent advances in the FCM analysis of hematopoietic disorders. The chapters have been revised to incorporate new text and figures. A companion CD containing case studies is also included. The volume is aimed at hematopathologists, hematologists, pathologists, and laboratory technicians.

Recenzijos

"The first edition of this book was wonderful, and this updated edition continues the tradition of excellence.  You need this book for ready access if you do hematopathology." -Doody's Book Review, Weighted Numerical Score:96 - 4 Stars

From the reviews of the second edition:

"The book is nicely illustrated and contains numerous colour figures illustrating the broad variety of flow cytometry applications in various haematological conditions. The book is very well suited for clinical pathologists, assistants in training in the field of laboratory medicine and clinical pathology, medical technicians and researchers working in clinical haematology laboratories, as well as clinical haematologists who want to get familiar with the recent evolutions in diagnostic laboratory medicine." (Joris Delanghe, Acta Clinica Belgica, Vol. 63 (2), 2008)

Preface to the Second Edition ix
Preface to the First Edition xi
Acknowledgments xiii
List of Abbreviations
xv
List of Case Studies
xvii
Approach to flow cytometry: General considerations
Reasons for the necessity of proper data analysis
2(2)
The pitfalls of the FCM data format of ``percent positive'' per antibody tested
2(2)
General aspects of FCM data analysis and interpretation
4(3)
Other applications of FCM in hematopathology
7(2)
Maturation and differentiation of hematopoietic elements: An overview based on the immunologic markers currently in use in the FCM laboratory
9(4)
FCM immunophenotyping and DNA analysis: Practical aspects that can affect data analysis and interpretation
Sample selection
13(3)
Liquid specimens
14(1)
Solid tissue specimens
15(1)
Preparing nucleated cell suspensions
16(1)
Cell yield and viability
16(1)
Sample staining
16(3)
Surface antigens
17(1)
Intracellular antigens
17(1)
DNA content
18(1)
Data acquisition
19(3)
Calibration
19(1)
Color compensation
19(1)
List mode data collection
20(1)
Exclusion of nonviable cells
21(1)
Antibody panel design
22(9)
Antibody selection
23(1)
Anti-light chain antibodies
23(3)
Fluorochrome conjugation
26(5)
Comprehensive antibody panels
31(3)
Disease-oriented antibody panels
31(1)
Antibody panels oriented by specimen type
32(2)
Tailored panels and add-on testing
34(3)
Minimal residual disease
36(1)
FCM immunophenotyping data representation
37(13)
Analysis panels
37(1)
Color display
38(3)
Approach to DNA data analysis
41(1)
DNA ploidy
42(1)
S-phase
42(8)
FCM data analysis on nearly homogeneous samples
FCM parameters
50(21)
Forward scatter
50(3)
Side scatter
53(1)
Fluorescence
54(10)
Heterogeneous fluorescence intensity (bimodal, variable)
64(7)
Fluorescence dynamic range
71(1)
Strategy to the visual review of FCM immunophenotyping data
71(2)
Common SSC/CD45 patterns
73(13)
Assessment of the blast population
73(8)
Immature neoplastic cells with downregulated CD45
81(2)
SSC/CD45 in mature lymphoid disorders
83(3)
Other dot plot patterns useful in acute leukemia diagnosis
86(20)
Useful antigenic features in AML
86(9)
Myeloid phenotypic abnormalities and MRD detection
95(3)
Precursor B-ALL versus bone marrow B-cell progenitors
98(1)
Useful antigenic features in precursor T-lymphoma/leukemia
99(7)
Evaluation of mature lymphoid malignancies
106(60)
Assessment of surface light chain expression
106(2)
Assessment of pan B-cell antigens
108(4)
Useful antigenic features in mature B-cell malignancies
112(1)
CD 10 expression: Follicular center cell lymphomas
112(5)
Pattern of CD20 and CD11c coexpression
117(6)
CD5 expression
123(3)
Aberrant B-cell profile
126(5)
Identification of abnormal mature T-cells
131(19)
Useful antigenic features in mature T-cell malignancies
150(16)
Assessing the biological behavior of mature lymphoid neoplasms
166(5)
Dot plot patterns in histiocytic proliferations and nonhematopoietic malignancies
171(4)
FCM data analysis on heterogeneous specimens
Identifying normal FCM samples
175(45)
Benign/reactive solid lymphoid tissue (e.g., lymph nodes, tonsils)
175(4)
Pattern of CD10/CD20 coexpression: Distinction between FRFH and FCC lymphoma
179(8)
Normal peripheral blood and normal bone marrow
187(3)
Blast region
190(2)
Bone marrow B-cell precursors
192(1)
Lymphocytes
192(16)
Monocytes
208(1)
Plasma cells
209(4)
Erythroid precursors
213(3)
Maturing myeloid cells
216(4)
Abnormal heterogeneous samples with a detectable immature neoplastic population
220(13)
Blasts of lymphoid lineage
221(1)
Blasts of myeloid lineage
222(2)
AML
224(2)
High-grade MDS and MPD with increased blasts
226(7)
Minimal residual disease
233(1)
Abnormal heterogeneous samples with detectable mature neoplastic populations
233(27)
Abnormal mature B-cells
238(1)
Evaluation of CD5 and CD23
238(4)
FCM features suggestive of anti-CD20 therapy
242(3)
Abnormal mature T-cells and NK cells
245(10)
Abnormal plasma cells present
255(5)
Abnormal blood or bone marrow samples with no detectable neoplastic cells
260(25)
Altered cellular composition and abnormal SSC
262(1)
Increased monocytic elements
262(1)
Increased eosinophils
262(3)
Conspicuous basophils or mast cells
265(1)
Abnormal SSC in granulocytes
265(8)
Abnormal antigenic maturation in myeloid or erythroid precursors
273(1)
Antigenic abnormalities in myeloid precursors
273(7)
Antigenic abnormalities in erythroid precursors
280(1)
Identifying low-grade MDS
280(5)
Coexisting malignancies
285(4)
FCM interpretation and reporting
Immature hematopoietic malignancies
289(12)
ALL/lymphoblastic lymphoma
290(2)
Myeloid malignancies
292(1)
AML-M3
292(1)
AML with minimal maturation
292(1)
AML with maturation
292(2)
AML with monocytic differentiation
294(1)
AML with erythroid hyperplasia
295(1)
AML with megakaryocytic differentiation
295(1)
MPD and MDS
295(5)
Acute leukemias with a multilineage antigenic profile
300(1)
Mature lymphoid malignancies
301(32)
B-cell LPD/NHL
302(1)
CD 10 expression
302(4)
Coexpression of CD11c, CD25 and CD103
306(1)
Coexpression of CD5 and CD23
306(1)
CD5+ CD23- B-cell neoplasms
307(3)
CD45 and/or pan B-cell antigens markedly downregulated
310(1)
Nondescript B-cell phenotype and high FSC
311(3)
Nondescript B-cell phenotype and low FSC
314(4)
Monoclonal B-cells of undetermined significance
318(1)
Plasma cell dyscrasias
318(2)
T-cell LPD/NHL
320(1)
CD4+ T-cell LPD/NHL
321(2)
CD8+ disorders
323(6)
CD30+ lymphoma
329(4)
FCM reporting
333(2)
Suggested reading 335(6)
Appendix: Using the case studies CD-ROM 341(2)
Index 343


Daugiau apie elektronines knygas Daugiau apie elektronines knygas
Pastovi nuoroda: https://www.kriso.lt/db/97815974516282e.html
Raktažodžiai: